Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan

European Journal of Clinical Investigation

Volumn 36, Issue SUPPL. 3, 2006, Pages 16-24

  Beghetti, M ^a,b  

^a Children s University Hospital   (Switzerland)

^b Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

Author keywords

Bosentan; Congenital heart defects; Endothelin; Paediatrics; Pulmonary arterial hypertension; Treatment

Indexed keywords

AMBRISENTAN; AMINOTRANSFERASE; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ILOPROST; MINERALOCORTICOID ANTAGONIST; NIFEDIPINE; NITROUS OXIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; SILDENAFIL; SITAXSENTAN; TERBOGREL; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UNIPROST; VASODILATOR AGENT; WARFARIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CARDIOPULMONARY FUNCTION; CATHETER INFECTION; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; EXERCISE; EXPERIENCE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMODYNAMICS; HUMAN; JAW PAIN; LEG PAIN; LIVER TOXICITY; NAUSEA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHILD; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, ENDOTHELIN; SULFONAMIDES; VASODILATOR AGENTS;

EID: 33746858993     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01681.x     Document Type: Conference Paper

References (72)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-7.
2. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7.
3. Rosenzweig EB, Barst RJ. Idiopathic pulmonary arterial hypertension in children. Curr Opin Pediatr 2005;17:372-80.
4. Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J 2003;21:155-76.
5. Grunig E, Koehler R, Miltenberger-Miltenyi G, Zimmermann R, Gorenflo M, Mereles D et al. Primarypulmonary hypertension in children may have a different genetic background than in adults. Pediatr Res 2004;56:571-8.
6. Harrison RE, Berger R, Haworth SG, Tulloh R, Mache CJ, Morrell NW et al. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 2005;111:435-41.
7. Wagenvoort CA. The pathology of primary pulmonary hypertension. J Pathol 1970; 101.
8. Yamaki S, Wagenvoort CA. Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients. Br Heart J 1985;54:428-34.
9. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999;99:1197-208.
10. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004;110:660-5.
11. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
12. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:78S-92S.
13. Rosenzweig EB, Widlitz AC, Barst RJ. Pulmonary arterial hypertension in children. Pediatr Pulmonol 2004;38:2-22.
14. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:697-704.
15. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997;112:714-21.
16. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
17. Langleben D, Christman BW, Barst RJ, Dias VC, Galie N, Higenbottam TW et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002;143:E4.
18. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-70.
19. Barst RJ. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 1986;89:497-503.
20. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
21. McLaughlin VV. Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
22. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
23. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized controlled trial. Ann Intern Med 2000;132:425-34.
24. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
25. Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000;117:14-8.
26. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82.
27. Horn EM, Barst RJ, Poon M. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000;118:1229-30.
28. Fishman AP. Epoprostenol (prostacyclin) and pulmonary hypertension. Ann Intern Med 2000;132:500-2.
29. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003;2:123-37.
30. Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 2004;93:943-6.
31. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
32. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25.
33. Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extra-corporeal circulation procedures. Drugs 1992;43:889-924.
34. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
35. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-70.
36. Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003;124:1294-304.
37. Beghetti M, Berner M, Rimensberger PC. Long-term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. Heart 2001;86:E10.
38. Tissieres P, Nicod L, Barazzone-Argiroffo C, Rimensberger PC, Beghetti M. Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension. Ann Thorac Surg 2004;78:e48-50.
39. Yuan XJ, Tod ML, Rubin LJ, Blaustein MP. NO hyperpolarizes pulmonary artery smooth muscle cells and decreases the intracellular Ca2+ concentration by activating voltage-gated K+ channels. Proc Natl Acad Sci U S A 1996;93:10489-94.
40. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-4.
41. Wessel DL, Adatia I. Clinical applications of inhaled nitric oxide in children with pulmonary hypertension. Adv Pharmacol 1995;34:475-504.
42. Berner M, Beghetti M, Spahr-Schopfer I, Oberhansli I, Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 1996;77:532-5.
43. Channick RN, Newhart JW, Johnson FW, Williams PJ, Auger WR, Fedullo PF et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996;109:1545-9.
44. Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002;90:677-80.
45. Archer SL, Huang JM, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A 1994;91:7583-7.
46. Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 1991;308:191-7.
47. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149-53.
48. Sastry BK, Narasimhan C, Reddy NK, Anand B, Prakash GS, Raju PR et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 2002;54:410-4.
49. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005;111:3274-80.
50. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-22.
51. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-64.
52. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
53. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research 'Work in progress'. Circulation 2000;102:2781-91.
54. Cacoub P, Dorent R, Maistre G, Nataf P, Carayon A, Piette C et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 1993;71:448-50.
55. Cacoub P, Dorent R, Nataf P, Carayon A. Endothelin-1 in pulmonary hypertension. N Engl J Med 1993;329:1967-8.
56. Uguccioni M, Pulsatelli L, Grigolo B, Facchini A, Fasano L, Cinti C et al. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 1995;48:330-4.
57. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9.
58. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26:1581-5.
59. Bauer M, Wilkens H, Langer F, Schneider SO, Lausberg H, Schafers HJ. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002;105:1034-6.
60. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
61. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
62. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372-82.
63. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2005 (doi: 10.1136).
64. Beghetti M, Ivy D, Barst R. Clinical experience with bosentan in children with pulmonary arterial hypertension [abstract 171]. Eur J Clin Invest 2005;35 (Suppl. 2):58.
65. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
66. R) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children. Z Kardiol 2005;94:570-4.
67. Humbert M, Kiely DG, Carlsen J, Hoeper MM. Long-term safety profile of bosentan in daily practice [abstract 173]. Eur J Clin Invest 2005;35 (Suppl. 2):58.
68. Beghetti M, Humbert M, Hoerper M. Safety experience with bosentan in children under 12 years with pulmonary arterial hypertension: TRAX database [abstract 182]. Eur J Clin Invest 2005;35 (Suppl. 2):61.
69. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.
70. Galie N, Langleben D, Badesch D, Frost A, Lawrence EC, Naeije R et al. STRIDE-2 Trial: a placebo-controlled study for sitaxsentan in pulmonary arterial hypertension. Eur Heart J 2005;26 [abstract 26].
71. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35.
72. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006;92:664-70.